QuartrQuartr

RIGL: Commercial expansion and pipeline advances drive profitability and future growth

閱讀少於1分鐘

Strong commercial growth driven by three expanding products and disciplined financial management has enabled robust profitability and cash generation. Pipeline progress is highlighted by R289 for low-risk MDS and multiple collaborations, with a focus on in-licensing synergistic assets and expanding into new indications.

Based on Rigel Pharmaceuticals, Inc. [RIGL] Jefferies London Healthcare Conference 2025 Audio Transcript — Nov. 18 2025

免責聲明